Met Life Investment Management, LLC Imago Bio Sciences, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

May 10, 2024
SELL
$15.03 - $35.96 $63,817 - $152,686
-4,246 Reduced 23.17%
14,080 $506,000
Q4 2022

Jun 14, 2023
BUY
$15.03 - $35.96 $211,622 - $506,316
14,080 New
14,080 $506,000
Q4 2022

Mar 22, 2023
SELL
$15.03 - $35.96 $63,817 - $152,686
-4,246 Reduced 23.17%
14,080 $506,000
Q4 2022

Feb 15, 2023
SELL
$15.03 - $35.96 $63,817 - $152,686
-4,246 Reduced 23.17%
14,080 $506,000
Q3 2022

May 10, 2024
BUY
$14.15 - $19.5 $81,447 - $112,242
5,756 Added 45.79%
18,326 $275,000
Q3 2022

Jun 14, 2023
BUY
$14.15 - $19.5 $259,312 - $357,357
18,326 New
18,326 $275,000
Q3 2022

Mar 22, 2023
BUY
$14.15 - $19.5 $81,447 - $112,242
5,756 Added 45.79%
18,326 $275,000
Q3 2022

Nov 14, 2022
BUY
$14.15 - $19.5 $81,447 - $112,242
5,756 Added 45.79%
18,326 $276,000
Q2 2022

Jun 20, 2023
BUY
$11.81 - $20.92 $148,451 - $262,964
12,570 New
12,570 $168,000
Q1 2022

May 10, 2024
BUY
$16.97 - $25.0 $213,312 - $314,250
12,570 New
12,570 $242,000
Q1 2022

Jun 20, 2023
BUY
$16.97 - $25.0 $213,312 - $314,250
12,570 New
12,570 $242,000
Q1 2022

Mar 22, 2023
SELL
$16.97 - $25.0 $25,624 - $37,750
-1,510 Reduced 10.72%
12,570 $242,000
Q1 2022

May 12, 2022
BUY
$16.97 - $25.0 $213,312 - $314,250
12,570 New
12,570 $242,000

Others Institutions Holding IMGO

# of Institutions
2
Shares Held
19.3K
Call Options Held
0
Put Options Held
0
View Full List

About Imago BioSciences, Inc.

IMGO Quotes by TradingView
  • Ticker IMGO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,741,600
  • Description
  • Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment o...
More about IMGO
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email